Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Eli Lilly and Co LLY

Eli Lilly and Company is a medicine company. The Company discovers, develops, manufactures and markets products in the human pharmaceutical products segment. Its diabetes, obesity and other cardiometabolic products include Basaglar, Humalog, Mounjaro, Trulicity and Zepbound. Its oncology products include Alimta, Retevmo, Tyvyt and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh and Taltz. Its neuroscience products include Cymbalta and Emgality. Its other products and therapies include Cialis and Forteo. It manufactures and distributes its products through facilities in the United States (U.S.), including Puerto Rico, and in Europe and Asia. The Company, through its subsidiary, POINT Biopharma Global Inc., is engaged in radiopharmaceutical discovery, development, and manufacturing, as well as clinical and pre-clinical radioligand therapies. It is also developing oral small molecule inhibitor of a4ß7 integrin (known as MORF-057) for inflammatory bowel disease (IBD).


NYSE:LLY - Post by User

Bullboard Posts
Post by camper244on May 23, 2013 7:00am
350 Views
Post# 21430741

VALUE BUY- CS: HRT will pay ~$25 M for BREACHING t

VALUE BUY- CS: HRT will pay ~$25 M for BREACHING t

CREDIT  SUISSE  gives  credence  and  monetary  value  on  TID  case   against  HRT.

CRDIT  SUISSE  estimated  few  days  ago    that    HRT   will  pay   ~$0.25/share   for   breaching  the terms  of  its   two  contracts   with  TID  (Tuscany  International  Drilling)   in  2012.

CS   is  talking  about  the   two  heliportable  rigs   that   HRT   contracted    from  TID  and  terminated   just   because   HRT   hit   some   dry  holes......

This  is   about   $25  million   that  HRT   will  pay  to   TID.

You  can  contact  CS   to   confirm  it  or  read  below.  fyi,  1R$= $0.5

 
HRT Participacoes S.A. (HRTP3, Neutral, TP R$4.3/sh)
Dry, and subcommercial

Dry, and ‘dry’. After the 11th well in the Solimoes basin and the first one in Namibia, little comfort can investors get from HRT well results. HRT-11 was a dry hole, despite being drilled with new seismic and located on a supposedly oilier region within the Solimoes. In Namibia, Wingat found oil but in no commercial quantities. HRT is ‘pleased’ with the results and says finding two well-developed source rocks bode well for its Namibian efforts, which will continue with two other wells (Murombe, the next one, will be spud end of May). Namibia is frontier exploration and requires patience to be opened, a quality which the equity markets do not possess. 

Wingat vs Kabeljou. On September 10th 2012, Chariot shares fell 66% after results from the Kabeljou well. We do not think the HRT price reaction will be as extreme (Chariot shares were significantly above cash prior to the well, HRT shares are not), but we find similarities in the two releases. Both cite a less-developed reservoir than anticipated as key reason for subcommercial volumes of hydrocarbon. Both cite developed source rock as key positives. HRT has frequently mentioned the key uncertainty in Namibia is the potency of the source rocks to fill the reservoirs. It seems the source rocks are there. Let’s hope the reservoirs will be, too.

Is there a ‘floor’? HRT’s high-impact value creation proposition lies mostly outside the company’s balance sheet. If exploration does not work, the balance sheet matters as it gives investors reference of what the company would be left with in the event it does not monetise oil or gas in Namibia / Solimoes. And here, HRT not having debt is an asset. Taking a closer look at the balance sheet, we conclude that below R$2.5/sh, there would be interesting optionality to allow HRT to spend most of its cash for exploration to work-out. We see R$1.6/sh from Polvo, helicopters held for sale, guaranteed deposits, and other hard assets sold at 50% of book value, minus R$0.5/sh from working cap and Tuscany claims, and R$1.2/sh from ‘residual’ cash and monetisation of existing tax losses. Monetisation of the $1.4bn intangibles in the balance sheet via writedowns and tax-losses benefits could add R$1.6/sh, and a preliminary view of monetisation of Solimoes gas further R$1.0/sh.

Bullboard Posts